Mankind Pharma, one of India’s leading pharmaceutical companies, on Monday announced its entry into the topical analgesic market through its consumer business division.
According to the company’s press statement, the company is introducing Nimulid Strong, a revolutionary gel and spray formulation specifically designed to address neck pain, a condition that significantly impacts overall body function.
“Nimulid Strong boasts a unique selling proposition of containing 2X diclofenac concentration, promising faster relief for consumers suffering from neck pain. This strategic move is in alignment with Mankind Pharma’s commitment to expanding its consumer healthcare portfolio and addressing critical pain management needs,” the company said in a statement.
The launch is accompanied by a compelling video campaign titled #GardanHilaateRaho that highlights the cultural significance of neck movements in India.
“Our entry into the topical analgesic market with Nimulid Strong marks a pivotal moment for Mankind Pharma’s consumer business. By focusing on neck pain, which can severely hinder daily life, we aim to empower millions of Indians to live and communicate more freely. Our innovative 2X diclofenac formulation, paired with a resonant video campaign, showcases how integral neck movements are in daily interactions. The campaign’s message, ‘Gardan dard ka specialist’ (Specialist in neck pain), positions Nimulid Strong as the go-to solution for this specific, yet widespread problem,” Joy Chatterjee, Vice President, Sales and Marketing Head, Consumer Business Unit, Mankind Pharma Ltd, said in a statement.
Nimulid Strong will be available in both gel and spray variants, offering consumers flexibility in application. The product is set to be distributed across pharmacies and modern trade outlets nationwide, supported by an extensive marketing campaign across various media platforms.
With the topical analgesic market in India valued at ₹1488 crore, according to IQVIA, Mankind Pharma’s launch of Nimulid Strong arrives at a pivotal moment. This strategic move aligns with the company’s commitment to delivering high-quality, affordable healthcare solutions. By focusing on specific pain management needs, Nimulid Strong represents a significant advancement in Mankind Pharma’s consumer healthcare segment, positioning the company to capture a substantial share of the expanding market through its established distribution network and strong brand reputation, it stated.
